Mandate

Vinge advises Biotage in connection with its acquisition of PhyNexus

December 06, 2018 Capital Markets and Public M&A

Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acquisition of PhyNexus, Inc. (“PhyNexus”), financed through a combination of newly issued shares and existing cash at hand.


The transaction is expected to be completed in January 2019 and is subject to customary closing conditions.

Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 410 employees and had sales of 748 MSEK in 2017.

Vinge’s team consists of Dain Hård Nevonen, Malte Hedlund and Josephine Andersson. 

Related

Vinge advises Smart Eye on acquisition of Sightic Analytics

Smart Eye has entered into an agreement to acquire all shares in Sightic Analytics for a fixed purchase price of SEK 60.5 million, to be paid with newly issued shares in Smart Eye, and an additional purchase price of up to SEK 50 million, conditional upon certain financial and operational targets being met.
February 24, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB.
February 22, 2026

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026